| Project/Area Number |
24590701
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
WATANABE Naoki 札幌医科大学, 名誉教授 (10158644)
TANAKA Maki 札幌医科大学, 医学部, 助教 (40207139)
KURIBAYASHI Kageaki 札幌医科大学, 医学部, 講師 (50381257)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 新規治療標的 / 肺癌 / 抗癌剤耐性 / 再発 / 予測マーカー / 幹細胞複製分子 / 治療標的 / 耐性予測 / 治療耐性因子 / 幹細胞 / 複製分子 |
|---|
| Outline of Final Research Achievements |
In this study we aimed to identify novel therapeutic target in lung cancer. For that purpose, we examined the potentiality of SALL4 that expresses especially at early stages of cancer and that its inhibition of the expression leads to growth arrest of the cells. Appropriate level of the inhibition of SALL4 in lung cancer cells resulted in the augmentation of the sensitivity of all investigated anticancer drugs at quite low concentration. Moreover, in lung cancer patients those freshly entried chemotherapy after surgical resection, amounts of SALL4 mRNA expression before chemotherapy was higher in the group showing recurrence after chemotherapy and was further higher in the group showing shorter survival. The data indicate that SALL4 induces drug resistance and could be a novel therapeutic target in lung cancer patients.
|
